PRG4 and hepatocellular carcinoma: The lack of synergistic interaction between PRG4 and regorafenib in reducing in vitro endothelial tubulogenesis, as we observed, could be related to the existence of additional levels of complexity behind the function associated with PRG4 activities within the HCC microenvironment.